Ratings Eurobio Scientific

Equities

ALERS

FR0013240934

Market Closed - Euronext Paris Other stock markets 11:35:25 2024-04-29 am EDT			5-day change	1st Jan Change
14.22 ^EUR	-0.42%		-3.92%	-13.61%

Apr. 11	Eurobio Scientific: 2023 results down, share price falls	CF
Jan. 30	Eurobio Scientific Société anonyme acquired Alpha Biotech Ltd.	CI

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

The company is in a robust financial situation considering its net cash and margin position.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

As estimated by analysts, this group is among those businesses with the lowest growth prospects.
The company's earnings growth outlook lacks momentum and is a weakness.
The firm trades with high earnings multiples: 33.07 times its 2023 earnings per share.
For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
EUROBIO SCIENTIFIC	-13.61%	156M	-
IQVIA HOLDINGS INC.	+1.77%	42.75B	B
LONZA GROUP AG	+47.70%	41.61B	A
MODERNA, INC.	+12.24%	41.34B	B-
CELLTRION, INC.	-8.83%	26.59B	C
ICON PUBLIC LIMITED COMPANY	+7.44%	25.49B	B-
ALNYLAM PHARMACEUTICALS, INC.	-23.01%	18.12B	B
MEDPACE HOLDINGS, INC.	+30.56%	12.24B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.82%	11.76B	C+
UNITED THERAPEUTICS CORPORATION	+8.35%	11B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes